ºÃÉ«ÏÈÉú

With the development of monoclonal antibody therapies for Alzheimer’s disease, neurologists and cognitive specialists will play an important role in providing safe and equitable access to these treatments. These therapies have been shown to slow down clinical progression, albeit with significant side effects.

The AAN’s Cognitive Therapies Implementation Guide is designed to help clinicians, business administrators, and organizations: 

• Navigate the conceptualization, implementation, and maintenance of patients under consideration for monoclonal antibody therapies
• Provide safe, broad, and equitable access to monoclonal therapies
• Establish flexible protocols that evolve over time

Developing and implementing an appropriate protocol and system will be fundamental for clinical practices. The AAN Medical Economics and Practice (MEP) Committee created a Cognitive Therapies Work Group to develop broad suggestions that may serve as resources for practices considering or offering these therapies.